As described in more detail below, there are a number of receptor tyrosine kinase genes that are mutated in canine melanomas and tyrosine kinase inhibitor drugs are already commercially available and used clinically in canine cancer patients 64, but to date no trials have been published using these compounds in canine melanoma. This evidence concerns the gene NTRK1 and melanoma.